Pim

信号通路图

研究领域

抑制剂选择性比较

特异性亚型抑制剂

Pim产品

所有产品 Pim抑制剂(7) 新Pim产品

产品目录	产品描述	文献引用	实验数据
S2198	SGI-1776 free base SGI-1776 free base是一种新型的，ATP竞争性Pim1抑制剂，无细胞试验中IC50为7 nM，比作用于Pim2和Pim3选择性分别高50和10倍，也有效作用于Flt3和haspin。Phase 1。	Cancer Lett, 2019, 440-441:1-10 Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):175-189 Exp Cell Res, 2017, 352(2):403-411	VCaP cells were steroid starved overnight then treated with 10nM R1881 and PIM kinase inhibitor SGI-1776 as indicated for 4 hours. Total protein lysates were analyzed by Western blot with antibodies against P-AR S213, AR (total), P-4EBP1 Thr 37/46, and tubulin.
S8005	SMI-4a SMI-4a是一种有效的Pim1抑制剂，IC50为17 nM，作用于Pim-2适度有效，抑制其他丝/苏氨酸或酪氨酸激酶作用不显著。	Arthritis Rheumatol, 2019, 71(8):1308-1318 Int Immunopharmacol, 2019, 73:568-574 Onco Targets Ther, 2018, 11:6647-6656	Loss of proliferation in ATL-derived cell lines by the Pim-kinase inhibitors, Smi-4a (C). Cell counts were repeated at least twice. Results represent the percentage of cells alive after 5 days of Pim inhibitor treatment, compared with 5 days treated with DMSO. For Smi-4a treatment, cells were treated with 0, 10, or 20 μM Smi-4a. Normal PBMCs (n = 2) were used as a control. Western blots indicate loss of Pim1 targets, p-4EBP1 (Thr37/46), p-p70S6K (Thr389), and loss of pBad (Ser20) (negligible for Smi-4a) after 24 hours with 0, 10, 20, or 40 μM Smi-4a or DMSO control.
S6497^New	SMI-16a SMI-16a是选择性Pim激酶抑制剂，对Pim1和Pim2的IC50值分别为150 nM和20 nM。
S8800^New	INCB053914 INCB053914是一种新型的、ATP竞争性的PIM kinases抑制剂，对PIM1、PIM2、PIM3的IC50值分别为0.24 nM、30 nM和0.12 nM。
S7985	PIM447 (LGH447) PIM447是一种新型的、泛PIM激酶抑制剂，对PIM1、PIM2、PIM3的Ki值分别为6 pM、18 pM、9 pM。它还能抑制 GSK3β, PKN1和PKCτ，但抑制效力较小，IC50在1-5 μM范围间。	Transl Oncol, 2018, 12(2):336-349	(H) MV4-11 cells were treated for 6 hours with or without 3 ng/ml BZM, 10 μM PF, or 3 μM PIM, as indicated, and analyzed.
S7104	AZD1208 AZD1208是一种有效的口服可利用的Pim kinase抑制剂，在无细胞试验中对Pim1, Pim2, and Pim3的IC50分别为0.4 nM，5 nM，和 1.9 nM。Phase 1。	Cancer Cell, 2019, 36(2):179-193 Nat Cell Biol, 2019, 21(6):778-790 Arthritis Rheumatol, 2019, 71(8):1308-1318	Loss of proliferation in ATL-derived cell lines by the Pim-kinase inhibitor AZD1208 (D). Cell counts were repeated at least twice. Results represent the percentage of cells alive after 5 days of Pim inhibitor treatment, compared with 5 days treated with DMSO. For AZD1208, cells were treated with 0, 5, or 10 μM AZD1208. Normal PBMCs (n = 2) were used as a control. Western blots indicate loss of Pim1 targets, p-4EBP1 (Thr37/46), p-p70S6K (Thr389), and loss of pBad (Ser20) (negligible for Smi-4a) after 24 hours with 0, 5, or 10 μM AZD1208; or DMSO control.
S7041	CX-6258 HCl CX-6258 HCl 是强效的可口服的pan-Pim kinase抑制剂，其对Pim1, Pim2, 和 Pim3的IC50分别为5 nM, 25 nM 和 16 nM。	Cancer Lett, 2019, 440-441:1-10 Exp Hematol Oncol, 2016, 10.1186/s40164-016-0060-3 Nat Chem Biol, 2016, 12(7):497-503

产品目录	产品描述	文献引用	实验数据
S2198	SGI-1776 free base SGI-1776 free base是一种新型的，ATP竞争性Pim1抑制剂，无细胞试验中IC50为7 nM，比作用于Pim2和Pim3选择性分别高50和10倍，也有效作用于Flt3和haspin。Phase 1。	Cancer Lett,2019, 440-441:1-10 Biochim Biophys Acta Mol Cell Res,2019, 1866(2):175-189 Exp Cell Res,2017, 352(2):403-411	VCaP cells were steroid starved overnight then treated with 10nM R1881 and PIM kinase inhibitor SGI-1776 as indicated for 4 hours. Total protein lysates were analyzed by Western blot with antibodies against P-AR S213, AR (total), P-4EBP1 Thr 37/46, and tubulin.
S8005	SMI-4a SMI-4a是一种有效的Pim1抑制剂，IC50为17 nM，作用于Pim-2适度有效，抑制其他丝/苏氨酸或酪氨酸激酶作用不显著。	Arthritis Rheumatol,2019, 71(8):1308-1318 Int Immunopharmacol,2019, 73:568-574 Onco Targets Ther,2018, 11:6647-6656	Loss of proliferation in ATL-derived cell lines by the Pim-kinase inhibitors, Smi-4a (C). Cell counts were repeated at least twice. Results represent the percentage of cells alive after 5 days of Pim inhibitor treatment, compared with 5 days treated with DMSO. For Smi-4a treatment, cells were treated with 0, 10, or 20 μM Smi-4a. Normal PBMCs (n = 2) were used as a control. Western blots indicate loss of Pim1 targets, p-4EBP1 (Thr37/46), p-p70S6K (Thr389), and loss of pBad (Ser20) (negligible for Smi-4a) after 24 hours with 0, 10, 20, or 40 μM Smi-4a or DMSO control.
S6497^New	SMI-16a SMI-16a是选择性Pim激酶抑制剂，对Pim1和Pim2的IC50值分别为150 nM和20 nM。
S8800^New	INCB053914 INCB053914是一种新型的、ATP竞争性的PIM kinases抑制剂，对PIM1、PIM2、PIM3的IC50值分别为0.24 nM、30 nM和0.12 nM。
S7985	PIM447 (LGH447) PIM447是一种新型的、泛PIM激酶抑制剂，对PIM1、PIM2、PIM3的Ki值分别为6 pM、18 pM、9 pM。它还能抑制 GSK3β, PKN1和PKCτ，但抑制效力较小，IC50在1-5 μM范围间。	Transl Oncol,2018, 12(2):336-349	(H) MV4-11 cells were treated for 6 hours with or without 3 ng/ml BZM, 10 μM PF, or 3 μM PIM, as indicated, and analyzed.
S7104	AZD1208 AZD1208是一种有效的口服可利用的Pim kinase抑制剂，在无细胞试验中对Pim1, Pim2, and Pim3的IC50分别为0.4 nM，5 nM，和 1.9 nM。Phase 1。	Cancer Cell,2019, 36(2):179-193 Nat Cell Biol,2019, 21(6):778-790 Arthritis Rheumatol,2019, 71(8):1308-1318	Loss of proliferation in ATL-derived cell lines by the Pim-kinase inhibitor AZD1208 (D). Cell counts were repeated at least twice. Results represent the percentage of cells alive after 5 days of Pim inhibitor treatment, compared with 5 days treated with DMSO. For AZD1208, cells were treated with 0, 5, or 10 μM AZD1208. Normal PBMCs (n = 2) were used as a control. Western blots indicate loss of Pim1 targets, p-4EBP1 (Thr37/46), p-p70S6K (Thr389), and loss of pBad (Ser20) (negligible for Smi-4a) after 24 hours with 0, 5, or 10 μM AZD1208; or DMSO control.
S7041	CX-6258 HCl CX-6258 HCl 是强效的可口服的pan-Pim kinase抑制剂，其对Pim1, Pim2, 和 Pim3的IC50分别为5 nM, 25 nM 和 16 nM。	Cancer Lett,2019, 440-441:1-10 Exp Hematol Oncol,2016, 10.1186/s40164-016-0060-3 Nat Chem Biol,2016, 12(7):497-503